EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Chimeric antigen receptor (CAR)-T cell therapy in the treatment of haematological malignancies

Karla O'Shea

International Undergraduate Journal of Health Sciences · 12.09.2023 · 3 (1)

DOI: 10.61862/2811-5937.1056 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Undergraduate Journal of Health Sciences, online erschienen am 12.09.2023. Verfasst von Karla O'Shea. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The use of chimeric antigen receptor T (CAR-T) cells in the treatment of haematological malignancies, particularly relapsed/refractory (R/R) B cell malignancies, has resulted in quite a high success rate. The most popular CAR-T cell therapy targets currently are CD19 and B-cell maturation antigen (BCMA), though many other innovative therapeutic targets are being investigated. According to the National Cancer Institute BCMA is defined as an antigen found on the surfaces of B cells and is overexpressed on malignant plasma cells. Additionally, CD19 controls B cells in an antigen receptor-dependent way and is produced throughout the B cell differentiation process, particularly during the malignant transformation of B cells (Zheng et al., 2020). Researchers are therefore attracted to CD19 as a potential target. However, side effects from CAR-T cell therapy, such as neurotoxicity and cytokine release syndrome (CRS) exist and could be severe or even fatal. Additionally, after receiving CAR-T cell therapy, patients can relapse due to antigen escape, 'on-target, off-tumour' toxicity, and an immunosuppressive tumour microenvironment. As a result, this review examines the application of CAR-T therapies including the current FDA-approved drugs and results from clinical trials, the limitations and difficulties associated with CAR-T cell therapy for haematological malignancies, and the prospects for this breakthrough therapy.

Zitieren

APA

O'Shea, K. (2023). Chimeric antigen receptor (CAR)-T cell therapy in the treatment of haematological malignancies. International Undergraduate Journal of Health Sciences, 3(1). https://doi.org/10.61862/2811-5937.1056

Vancouver

O'Shea K. Chimeric antigen receptor (CAR)-T cell therapy in the treatment of haematological malignancies. International Undergraduate Journal of Health Sciences. 2023;3(1). doi:10.61862/2811-5937.1056

BibTeX
@article{OShea2023,
  author = {O'Shea, Karla},
  title = {Chimeric antigen receptor (CAR)-T cell therapy in the treatment of haematological malignancies},
  journal = {International Undergraduate Journal of Health Sciences},
  year = {2023},
  volume = {3},
  number = {1},
  doi = {10.61862/2811-5937.1056}
}
Kostenlos starten →